More from Renaissance Capital

Intercept Pharmaceuticals files for a $75 million US IPO

By Renaissance Capital,  September 04, 2012, 05:03:35 PM EDT

Intercept Pharmaceuticals, a company focused on the development and commercialization of therapeutics for chronic liver disease, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering. Intercept originally filed confidentially on August 8, 2012. The New York, NY-based company, which was founded in 2002 and booked $3 million in sales for the 12 months ended 6/30/2012, plans to list on the NASDAQ under the symbol ICPT. BofA Merrill Lynch is the sole bookrunner on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: News Headlines, IPOs

Referenced Stocks:



Latest News Video

Vendor Brings Snow Cones Into Bathroom Stall at Astros Game
Vendor Brings Snow Cones Into Bathr...
McDonald's Offers Ludicrous 'Mega Potato' French Fries
McDonald's Offers Ludicrous 'Mega P...
What Is the Proper Way to Retire an American Flag?
What Is the Proper Way to Retire an...


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.21 0.10  0.75%
HPQ $ 24.86 3.63  17.10%
SIRI $ 3.545 0.01  0.28%
MU $ 11.39 0.47  4.30%
MSFT $ 34.15 0.46  1.33%
F $ 14.81 0.16  1.07%
QQQ $ 73.45 0.17  0.23%
GE $ 23.66 0.20  0.84%